Editorial

A new love affair — but will you respect me in the morning?

HemOnc Today, July 25, 2019
Derek Raghavan, MD, PhD
We have known for more than 50 years that immunotherapy is active against noninvasive bladder cancer, dating from the paradigm-altering work of…
Cover Story

Aggressive end-of-life care: A disservice to patients

HemOnc Today, July 25, 2019
The availability of more effective and less toxic anticancer agents has made it increasingly difficult for clinicians to discern when to discontinue…
Guidelines

NCCN Releases Inaugural Pediatric ALL Clinical Practice Guidelines

Cell Therapy Next, July 2019
The National Comprehensive Cancer Network recently released its first clinical practice guidelines for children with acute lymphoblastic leukemia…
Cover Story

Driving Killer CARs into Cancer

Cell Therapy Next, July 2019
Automobile pioneer Henry Ford once said of his best-selling Model T, “Any customer can have a car painted any color that he wants so long as…
Meeting News

Nonengineered T-cells may be ‘clinically meaningful’ for pancreatic cancer

July 19, 2019
More than half of patients with pancreatic adenocarcinoma showed clinical responses when treated with an investigational multiantigen-specific T-cell…
Feature

Intersection of radiotherapy, immunotherapy guides Penn’s new cancer research center

July 18, 2019
The Abramson Cancer Center at the University of Pennsylvania has been awarded a $12 million grant from the Mark Foundation for Cancer Research to…
Feature

TAPUR study fulfilling need to better understand targeted therapies, ASCO’s Schilsky says

July 15, 2019
The Targeted Agent and Profiling Utilization Registry , or TAPUR, study is fulfilling a need in clinical research across the United States for…
Molecular Oncology

Mind the gap: Precision medicine shortcomings in NSCLC

HemOnc Today, July 10, 2019
Howard (Jack) West, MD
This year’s ASCO Annual Meeting included several major successes that should translate to new molecular targets in advanced non-small cell lung…
Point/Counter

Should lenvatinib be used as first-line therapy for slowly progressing radioiodine-refractory thyroid carcinoma?

HemOnc Today, July 10, 2019
POINT Lenvatinib is my preference as a first-line therapy when patients need treatment beyond levothyroxine and thyroid-stimulating hormone suppression.
Cover Story

New treatments, new outcomes for refractory thyroid cancer

HemOnc Today, July 10, 2019
Thyroid cancer diagnoses are increasing rapidly in the United States. But, with an estimated incidence of four cases per million population, thyroid…